Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Impact of Clinical Trials on Cancer Care in Low- and Middle – Income Countries International Clinical Trials Workshop FLASCA, ASCO, NCI, ONS. September, 11-13 2014. Córdoba, Argentina Prof. Dra. Lucía Delgado Pebé Directora del Servicio de Oncología Clínica Hospital de Clínicas - Montevideo, Uruguay Presidente del Grupo Oncológico Cooperativo Uruguayo Cancer Incidence (IARC, 2014) CANCER year 2012 14.1 million new cases 1.3 million in Caribbean and Latin America CANCER by the year 2030 21.4 million new cases 1.7 million in Caribbean and Latin America All Cancer Mortality/Incidence Ratio (IARC, 2010) Latin America: 0.59 European Union: 0.43 USA: 0.35 Why to do Clinical Cancer Research in Developing Countries? (1) With regards to other regions there are differences in incidence and mortality The most frequent cancers may be different to those in developed countries regarding the primary location and biological characteristics. Cancer Incidence and Mortality Worldwide Less vs More Developed Countries INCIDENCE MORTALITY MEN Cancer Incidence and mortality .UICC, 2005. INCIDENCE MORTALITY WOMEN Cancer Incidence and mortality .UICC, 2005. Why to do Clinical Cancer Research in Developing Countries? (2) There can be ethnic differences in drug metabolization and tolerance to treatment and differences in response to therapy. Acces to and coverage of Health Services may not be similar. The Relevance of Cancer Research in Developing Countries As a consequence, studies conducted in developed countries may not respond to the needs and characteristics of the population and Health Systems in countries with fewer resources Local research can contribute to identify treatments that can be useful and also be affordable in less developed countries Academic vs Pharma Industry driven Clinical Research As clinical trials have become more expensive, the proportion financed by the pharmaceutical industry (PI) has increased. As a logical consequence, the Pl has a major influence on topics selected for clinical trials Why to do Academic Clinical Research? Treatment guidelines are based on clinical trials As a result of the growing sponsorhip of the PI, there exists an increasing influence of the commercial sponsors on therapeutic guidelines Clinical Trials in Latin America Academic Academic vs Sponsored vs Pharmaby Industry Pharma Driven Industry Pharmaceutical Industry sponsored investigation is important and should be continued BUT Academic, independent investigation should have a much more important role than the present one Academic vs Pharma Industry driven Clinical Research Pharmaceutical Industry Main objectives of industry driven and academic driven clinical trials Academy 1. Development of new drugs/interventions 3 2. Development of new therapeutic strategies (multidisciplinary, new combinations or indications of know drugs) 3. Rapid incorporation of new discoveries in clinical practice 4. identification of ineffective/ redundant therapeutic strategies Academic Clinical Trials in LA Main Concern: FUNDING Therapeutic clinical research is expensive which makes it difficult to be state funded HOWEVER What is the health care cost, if the standard of care is based on clinical studies that develop non affordable or non relevant treatments for our patients? Example: treatment of advanced Hepatocellular Carcinoma Sistemic Therapy of Advanced Hepatocellular Carcinoma Estudios SORAFENIB N= 137 (Fase II) JCO, 2006 Poliquimioterapia con GEMOX N= 34 (Fase II) Cancer, 2007 SORAFENIB Vs PLACEBO N= (Fase III) N Engl J Med, 2008 Respuestas objetivas Sobrevida sin progresion Sobrevida global 2.2% 4.2 meses 9.2 meses 18% 6.3 meses 11.5 meses 2.0% vs 1% 5.5 vs 2.8 meses 10.7 vs 7.9 meses Fase III (vs Placebo) Sistemic Therapy of Advanced Hepatocellular Carcinoma Open studies: “SORAFENIB WITH O WITHOUT CHEMOTHERAPY IN TREATING PATIENTS WITH ADVANCED HEPATOCARCINOMA” Source: clinicaltrials.gov Is GEMOX as efective as Sorafenib? Why to do Clinical Cancer Research in Developing Countries? A) ENSAYOS CLINICOS Academica PARA REALIZAR ESTUDIOS EN LOS QUE NO SE INTERESA LA INDUSTRIA FARMACEUTICA 1) IDENTIFICAR FACTORES PREDICTIVOS DE BENEFICIO CON TERAPIAS QUE HOY SE INDICAN A TODOS PARA BENEFICIAR UNOS POCOS (EJ BEVACIZUMAB) 2) PARA IDENTIFICAR TRATAMIENTOS EFECTIVOS DE BAJO COSTO (ENSAYAR DROGAS DE BAJO COSTO EN NUEVAS COMBINACIONES O INDICACIONES (LOS RESULTADOS PUEDEN SER MUY BUENOS. EJ: DOCETAXEL CON HT EN PRIMERA LINEA DE CA DE PROSTATA) O COMPARAR DROGAS DE ALTO COSTO CON Why to do Clinical Cancer Research in Developing Countries? (3) Clinical Research versus use of Clinical Guidelines in improving outcomes: • Survival rates of patients treated in centers participating in clinical trials tend to be better. Du Bois A et al, Int J Gynecol Cancer 2005 Peppercorn J et al, Lancet 2004 Hebert Croteau N et al, Breast Cancer Res Treat 2005 Fuente: The benefit of participating to clinical reserarch. N. Hébert-Crosteau, J. Brisson, J. Lamaire and J. Latreille. Breast Cancer Researcha and Treatment (2005) 91:279-281 Better outcomes for patients treated at hospitals that participate in clinical trials: (a) adherence; (b) mortality. Selby P , and Autier P Ann Oncol 2011;22:vii5-vii9 © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected] Why to do Clinical Cancer Research in Developing Countries? (5) • Development of research is essential to the development of a high quality, sustainable, health system • Scientifically trained oncologists are more able to analyze the information and to identify the relevant one Why to do Clinical Cancer Research in Developing Countries? (6) • To obtain data that allows to assess the efficacy and cost-benefit ratio of any intervention in the natural history of a disease (what applies in one population or environment does not necessarily apply in another) • The questions that need to be addressed to improve cancer care in developing countries frequently differ from those that are prioritized in developed ones The Importance of Multinational Clinical Trials In frequent and devastating neoplasms ( a little improvement in survival may be relevant) In rare tumors it substitutes small trials (carried out at the same time in several countries) that are inconclusive Clinical Research in Latin America NEEDS AND CHALLENGES FLASCA’s Perspectives To increase the participation in relevant multinational clinical studies, that comply with international ethic norms and with the current local regulation and conducted by a adequately trained team It should be offered to a greater percentage of patients, the possibility to participate in these kind of studies Clinical Research in Latin America NEEDS AND CHALLENGES FLASCA’s Perspectives To support: - research programs oriented to the local/regional problems - academic clinical studies that take into account the cancer characteristics at the local/regional level and treatments that can be financed in our countries Thank you!!